Stay updated on Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial

Sign up to get notified when there's something new on the Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    Revision number updated from v3.6.0 to v3.6.2, reflecting a newer page build/version. This is a backend/build metadata change and does not modify visible study data.
    Difference
    0.2%
    Check dated 2026-06-26T19:41:08.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    The history now records that the study is no longer recruiting participants. It also notes a new revision version v3.6.0 and the removal of the previous revision v3.5.5.
    Difference
    0.5%
    Check dated 2026-06-12T12:24:18.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    A new revision tag indicates the record was updated administratively, moving from v3.5.4 to v3.5.5.
    Difference
    0.1%
    Check dated 2026-06-05T08:43:22.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    The study record history shows the trial was terminated by the sponsor due to lack of efficacy, with updates to Study Status and Recruitment Status reflected across the page. The latest version adds a 'Results Posted' indicator and references the revised record (Revision: v3.5.4) dated 2026-05-12.
    Difference
    0.9%
    Check dated 2026-05-15T04:48:42.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    The record history adds a new revision entry (v3.5.3). It replaces the previous v3.5.2 and indicates an administrative update to the study record.
    Difference
    0.1%
    Check dated 2026-04-30T18:57:23.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    Version 3.5.2 adds comprehensive study data sections (Adverse Events, Outcome Measures, Baseline Characteristics, Participant Flow, IPDSharing, Eligibility, Arms and Interventions, Study Design, Study Description, Study Status, Study Identification, Recruitment Status). It updates the revision timeline to reflect the new changes (Revision: v3.5.2, dated 2026-03-25).
    Difference
    2%
    Check dated 2026-04-16T11:09:32.000Z thumbnail image

Stay in the know with updates to Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial page.